Reported Saturday, Nuvation Bio Revealed Findings From The Crucial Phase 2 TRUST-I Trial Of Their Experimental ROS1 Inhibitor, Taletrectinib At The ASCO 2024
$NUVB
Biotechnology: Pharmaceutical Preparations
Health Care
- Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study
- Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years
- TRUST-I is one of two registrational Phase 2 studies evaluating taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC